Glucagon-like peptide-1 receptor agonists and sodium−glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect

References

1. • Seshasai S.R.K.
   • Kaptoge S.
   • Thompson A.
   • Di Angelantonio M.
   • Gao P.
   • Sarwar N.
   • et al.
   Diabetes Mellitus, fasting glucose, and risk of cause-specific death.
   N Engl J Med. 2011; 364: 829-841https://doi.org/10.1056/NEJMoa1008862
   View in Article

   • Google Scholar
2. • Collaboration Emerging Risk Factors
   • E Di Angelantonio
   • Kaptoge S
   • Wormser D
   • Willeit P
   • Butterworth AS
   • Bansal N
   • et al.
   Association of Cardiometabolic Multimorbidity With Mortality.
   JAMA. 2015; 314: 52-60https://doi.org/10.1001/jama.2015.7008
   View in Article

   • Google Scholar
3. • Rawshani A.
   • Rawshani A.
   • Franzén S.
   • Eliasson B.
   • Svensson A.M.
   • Miftaraj M.
   • et al.
   Mortality and cardiovascular disease in type 1 and type 2 diabetes.
   N Engl J Med. 2017; 376: 1407-1418https://doi.org/10.1056/NEJMoa1608664
   View in Article

   • Google Scholar
4. • Juhaeri J.
   • Gao S.
   • Dai W.S.
   Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.
   Pharmacoepidemiol Drug Saf. 2009; 18: 497-503https://doi.org/10.1002/pds.1741
   View in Article

   • Google Scholar
5. • Lara-Rojas C.M.
   • Pérez-Belmonte L.M.
   • López-Carmona M.D.
   • Guijarro-Merino R.
   • Bernal-López M.R.
   • Gómez-Huelgas R.
   National trends in diabetes mellitus hospitalisation in Spain 1997–2010: analysis of over 5.4 millions of admissions.
   Eur J Intern Med. 2019; 60: 83-89https://doi.org/10.1016/j.ejim.2018.04.005
   View in Article

   • Google Scholar
6. • Pérez-Belmonte L.M.
   • Lara-Rojas C.M.
   • López-Carmona M.D.
   • Guijarro-Merino R.
   • Bernal-López M.R.
   • Gómez-Huelgas R.
   National trends in heart failure hospitalization rates in patients with diabetes mellitus: 1997-2010.
   Rev Esp Cardiol (Engl Ed). 2018; 71: 408-410https://doi.org/10.1016/j.rec.2017.04.028
   View in Article

   • Google Scholar
7. • Koye D.N.
   • Shaw J.E.
   • Reid C.M.
   • Atkins R.C.
   • Reutens A.T.
   • Magliano D.J.
   Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies.
   Diabet Med. 2017; 34: 887-901https://doi.org/10.1111/dme.13324
   View in Article

   • Google Scholar
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
   Lancet. 1998; 352: 837-853
   View in Article

   • Google Scholar
9. • Study Group ACCORD
   Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes.
   Diabetes Care. 2016; 39: 701-708https://doi.org/10.2337/dc15-2283
   View in Article

   • Google Scholar
10. • Collaborative Group ADVANCE
    • Patel A
    • MacMahon S
    • Chalmers J
    • Neal B
    • Billot L
    • Woodward M
    • et al.
    Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    N Engl J Med. 2008; 358: 2560-2572https://doi.org/10.1056/NEJMoa0802987
    View in Article

    • Google Scholar
11. • Duckworth W.
    • Abraira C.
    • Moritz T.
    • Reda D.
    • Emanuele N.
    • Reaven P.D.
    • et al.
    Glucose control and vascular complications in veterans with type 2 diabetes.
    N Engl J Med. 2009; 360: 129-139https://doi.org/10.1056/NEJMoa0808431
    View in Article

    • Google Scholar
12. • Gæde P.
    • Lund-Andersen H.
    • Parving H.-.H.
    • Pedersen O.
    Effect of a multifactorial intervention on mortality in type 2 diabetes.
    N Engl J Med. 2008; 358: 580-591
    View in Article

    • Google Scholar
13. • Nissen S.E.
    • Wolski K.
    Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
    N Engl J Med. 2007; 356: 2457-2471https://doi.org/10.1056/NEJMoa072761
    View in Article

    • Google Scholar
14. • Pfeffer M.A.
    • Claggett B.
    • Diaz R.
    • Dickstein K.
    • Gerstein H.C.
    • Køber L.V.
    • et al.
    Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.
    N Engl J Med. 2015; 373: 2247-2257https://doi.org/10.1056/NEJMoa1509225
    View in Article

    • Google Scholar
15. • Marso S.P.
    • Daniels G.H.
    • Brown-Frandsen K.
    • Kristensen P.
    • Mann J.F.
    • Nauck M.A.
    • et al.
    Liraglutide and cardiovascular outcomes in type 2 diabetes.
    N Engl J Med. 2016; 375: 311-322https://doi.org/10.1056/NEJMoa1603827
    View in Article

    • Google Scholar
16. • Marso S.P.
    • Bain S.C.
    • Consoli A.
    • Eliaschewitz F.G.
    • Jódar E.
    • Leiter L.A.
    • et al.
    Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes.
    N Engl J Med. 2016; 375: 1834-1844https://doi.org/10.1056/NEJMoa1607141
    View in Article

    • Google Scholar
17. • Holman R.R.
    • Bethel M.A.
    • Mentz R.J.
    • Thompson V.P.
    • Lokhnygina Y.
    • Buse J.B.
    • et al.
    Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.
    N Engl J Med. 2017; 377: 1228-1239https://doi.org/10.1056/NEJMoa1612917
    View in Article

    • Google Scholar
18. • Hernandez A.F.
    • Green J.B.
    • Janmohamed S.
    • Sr D'Agostino RB
    • Granger C.B.
    • Jones N.P.
    • et al.
    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Lancet. 2018; 392: 1519-1529https://doi.org/10.1016/S0140-6736(18)32261-X
    View in Article

    • Google Scholar
19. • Husain M.
    • Birkenfeld A.L.
    • Donsmark M.
    • Dungan K.
    • Eliaschewitz F.G.
    • Franco D.R.
    • et al.
    Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes.
    N Engl J Med. 2019; 381: 841-851https://doi.org/10.1056/NEJMoa1901118
    View in Article

    • Google Scholar
20. • Gerstein H.C.
    • Colhoun H.M.
    • Dagenais G.R.
    • Diaz R.
    • Lakshmanan M.
    • Pais P.
    • et al.
    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Lancet. 2019; 394: 121-130https://doi.org/10.1016/S0140-6736(19)31149-3
    View in Article

    • Google Scholar
21. • Gerstein H.C.
    • Sattar N.
    • Rosenstock J.
    • Ramasundarahettige C.
    • Pratley R.
    • Lopes R.D.
    • et al.
    Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes.
    N Engl J Med. 2021 Jun 28; https://doi.org/10.1056/NEJMoa2108269
    View in Article

    • Google Scholar
22. • Zinman B.
    • Wanner C.
    • Lachin J.M.
    • Fitchett D.
    • Bluhmki E.
    • Hantel S.
    • et al.
    Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
    N Engl J Med. 2015; 373: 2117-2128https://doi.org/10.1056/NEJMoa1504720
    View in Article

    • Google Scholar
23. • Neal B.
    • Perkovic V.
    • Mahaffey K.W.
    • de Zeeuw D.
    • Fulcher G.
    • Erondu N.
    • et al.
    Canagliflozin and cardiovascular and renal events in type 2 diabetes.
    N Engl J Med. 2017; 377: 644-657https://doi.org/10.1056/NEJMoa1611925
    View in Article

    • Google Scholar
24. • Wiviott S.D.
    • Raz I.
    • Bonaca M.P.
    • Mosenzon O.
    • Kato E.T.
    • Cahn A.
    • et al.
    Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
    N Engl J Med. 2019; 380: 347-357https://doi.org/10.1056/NEJMoa1812389
    View in Article

    • Google Scholar
25. • Cannon C.P.
    • Pratley R.
    • Dagogo-Jack S.
    • Mancuso J.
    • Huyck S.
    • Masiukiewicz U.
    • et al.
    Cardiovascular outcomes with ertugliflozin in type 2 diabetes.
    N Engl J Med. 2020; 383: 1425-1435https://doi.org/10.1056/NEJMoa2004967
    View in Article

    • Google Scholar
26. • Davies M.J.
    • D'Alessio D.A.
    • Fradkin J.
    • Kernan W.N.
    • Mathieu C.
    • Mingrone G.
    • et al.
    Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD).
    Diabetes Care. 2018; 41: 2669-2701https://doi.org/10.2337/dci18-0033
    View in Article

    • Google Scholar
27. • Mosenzon O.
    • Del Prato S.
    • Schechter M.
    • Leiter L.A.
    • Ceriello A.
    • DeFronzo R.A.
    • et al.
    From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
    Cardiovasc Diabetol. 2021; 20: 92https://doi.org/10.1186/s12933-021-01281-y
    View in Article

    • Google Scholar
28. • Varin E.M.
    • McLean B.A.
    • Lovshin J.A.
    Glucagon-like peptide-1 receptor agonists in adult patients with type 2 diabetes: review of cardiovascular outcome trials.
    Can J Diabetes. 2020; 44: 68-77https://doi.org/10.1016/j.jcjd.2019.08.011
    View in Article

    • Google Scholar
29. • Kristensen S.L.
    • Rorth R.
    • Jhund P.S.
    • Docherty K.F.
    • Sattar N.
    • Preiss D.
    • et al.
    Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Lancet Diabetes Endocrinol. 2019; 7: 776-785https://doi.org/10.1016/S2213-8587(19)30249-9
    View in Article

    • Google Scholar
30. • Górriz J.L.
    • Soler M.J.
    • Navarro-González J.F.
    • García-Carro C.
    • Puchades M.J.
    • D'Marco L.
    • et al.
    GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists.
    J Clin Med. 2020; 9: 947https://doi.org/10.3390/jcm9040947
    View in Article

    • Google Scholar
31. • Greco E.V.
    • Russo G.
    • Giandalia A.
    • Viazzi F.
    • Pontremoli R.
    • De Cosmo S.
    GLP-1 receptor agonists and kidney protection.
    Medicina (Kaunas). 2019; 55: 233https://doi.org/10.3390/medicina55060233
    View in Article

    • Google Scholar
32. • Nauck M.A.
    • Meier J.J.
    • Cavender M.A.
    • Abd El Aziz M.
    • Drucker D.J
    Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Circulation. 2017; 136: 849-870https://doi.org/10.1161/CIRCULATIONAHA.117.028136
    View in Article

    • Google Scholar
33. • Thomas M.C.
    The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes.
    Diabetes Metab. 2017; 43: 2S20-2S27https://doi.org/10.1016/S1262-3636(17)30069-1
    View in Article

    • Google Scholar
34. • Claggett B.
    • Lachin J.M.
    • Hantel S.
    • Fitchett D.
    • Inzucchi S.E.
    • Woerle H.J.
    • et al.
    Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease.
    Circulation. 2018; 138: 1599-1601https://doi.org/10.1161/CIRCULATIONAHA.118.033810
    View in Article

    • Google Scholar
35. • Koufakis T.
    • Papanas N.
    • Dimitriadis G.
    • Zebekakis P.
    • Kotsa K.
    Interpreting the results of the VERTIS-CV trial: is this the end of the "class effect" perspective?.
    J Diabetes. 2020; 12: 942-945https://doi.org/10.1111/1753-0407.13105
    View in Article

    • Google Scholar
36. • Li W.J.
    • Chen X.Q.
    • Xu L.L.
    • Li Y.Q.
    • Luo B.H.
    SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
    Cardiovasc Diabetol. 2020; 19: 130https://doi.org/10.1186/s12933-020-01105-5
    View in Article

    • Google Scholar
37. • Perkovic V.
    • Jardine M.J.
    • Neal B.
    • Bompoint S.
    • Heerspink H.J.L.
    • Charytan D.M.
    • et al.
    Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
    N Engl J Med. 2019; 380: 2295-2306https://doi.org/10.1056/NEJMoa1811744
    View in Article

    • Google Scholar
38. • Bhatt D.L.
    • Szarek M.
    • Pitt B.
    • Cannon C.P.
    • Leiter L.A.
    • McGuire D.K.
    • et al.
    Sotagliflozin in patients with diabetes and chronic kidney disease.
    N Engl J Med. 2021; 384: 129-139https://doi.org/10.1056/NEJMoa2030186
    View in Article

    • Google Scholar
39. • Bhatt D.L.
    • Szarek M.
    • Steg P.G.
    • Cannon C.P.
    • Leiter L.A.
    • McGuire D.K.
    • et al.
    Sotagliflozin in patients with diabetes and recent worsening heart failure.
    N Engl J Med. 2021; 384: 117-128https://doi.org/10.1056/NEJMoa2030183
    View in Article

    • Google Scholar
40. • McMurray J.J.
    • Solomon S.D.
    • Inzucchi S.E.
    • Køber L.
    • Kosiborod M.N.
    • Martinez F.A.
    • et al.
    Dapagliflozin in patients with heart failure and reduced ejection fraction.
    N Engl J Med. 2019; 381: 1995-2008https://doi.org/10.1056/NEJMoa1911303
    View in Article

    • Google Scholar
41. • Packer M.
    • Anker S.D.
    • Butler J.
    • Filippatos G.
    • Pocock S.J.
    • Carson P.
    • et al.
    Cardiovascular and renal outcomes with empagliflozin in heart failure.
    N Engl J Med. 2020; 383: 1413-1424https://doi.org/10.1056/NEJMoa2022190
    View in Article

    • Google Scholar
42. • Anker S.D.
    • Butler J.
    • Filippatos G.S.
    • Jamal W.
    • Salsali A.
    • Schnee J.
    • et al.
    Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2019; 21: 1279-1287https://doi.org/10.1002/ejhf.1596
    View in Article

    • Google Scholar
43. • Anker S.D.
    • Butler J.
    • Filippatos G.
    • Ferreira J.P.
    • Bocchi E.
    • Böhm M.
    • et al.
    Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    N Engl J Med. 2021; 385: 1451-1461https://doi.org/10.1056/NEJMoa2107038
    View in Article

    • Google Scholar
44. • Heerspink H.J.L.
    • Stefánsson B.V.
    • Correa-Rotter R.
    • Chertow G.M.
    • Greene T.
    • Hou F.F.
    • et al.
    Dapagliflozin in patients with chronic kidney disease.
    N Engl J Med. 2020; 383: 1436-1446https://doi.org/10.1056/NEJMoa2024816
    View in Article

    • Google Scholar

45. Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 20;5:632-44. doi:10.1016/j.jacbts.2020.02.004.

    View in Article

    • Google Scholar
46. • Mazidi M.
    • Rezaie P.
    • Gao H.K.
    • Kengne A.P.
    Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients.
    J Am Heart Assoc. 2017; 6e004007https://doi.org/10.1161/JAHA.116.004007
    View in Article

    • Google Scholar
47. • Cai X.
    • Yang W.
    • Gao X.
    • Chen Y.
    • Zhou L.
    • Zhang S.
    • et al.
    The Association Between the Dosage of SGLT2 Inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis.
    Obesity (Silver Spring). 2018; 26: 70-80https://doi.org/10.1002/oby.22066
    View in Article

    • Google Scholar
48. • Chino Y.
    • Samukawa Y.
    • Sakai S.
    • Nakai Y.
    • Yamaguchi J.
    • Nakanishi T.
    • et al.
    SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
    Biopharm Drug Dispos. 2014; 35: 391-404https://doi.org/10.1002/bdd.1909
    View in Article

    • Google Scholar
49. • Verma S.
    • McMurray J.J.V.
    SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.
    Diabetologia. 2018; 61: 2108-2117https://doi.org/10.1007/s00125-018-4670-7
    View in Article

    • Google Scholar
50. • L Lipscombe
    • Booth G.
    • Butalia S.
    • Dasgupta K.
    • Eurich D.T.
    • Goldenberg R.
    • et al.
    • Diabetes Canada Clinical Practice Guidelines Expert Committee
    Pharmacologic Glycemic Management of Type 2 Diabetes in Adults.
    Can J Diabetes. 2018; 42: S88-S103https://doi.org/10.1016/j.jcjd.2017.10.034
    View in Article

    • Google Scholar
51. • Garber A.J.
    • Handelsman Y.
    • Grunberger G.
    • Einhorn D.
    • Abrahamson M.J.
    • Barzilay J.I.
    • et al.
    Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 EXECUTIVE SUMMARY.
    Endocr Pract. 2020; 26: 107-139https://doi.org/10.4158/CS-2019-0472
    View in Article

    • Google Scholar
52. • Das S.R.
    • Everett B.M.
    • Birtcher K.K.
    • Brown J.M.
    • Januzzi Jr, J.L.
    • Kalyani R.R.
    • et al.
    Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the american college of cardiology solution set oversight committee.
    J Am Coll Cardiol. 2020; 76: 1117-1145https://doi.org/10.1016/j.jacc.2020.05.037
    View in Article

    • Google Scholar
53. • American Diabetes Association
    Cardiovascular disease and risk management: standards of medical care in diabetes–2021.
    Diabetes Care. 2021; 44: S125-S150https://doi.org/10.2337/dc21-S010
    View in Article

    • Google Scholar
54. • Elashoff M.
    • Matveyenko A.V.
    • Gier B.
    • Elashoff R.
    • Butler P.C.
    Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
    Gastroenterology. 2011; 141: 150-156https://doi.org/10.1053/j.gastro.2011.02.018
    View in Article

    • Google Scholar
55. • Palmer S.C.
    • Tendal B.
    • Mustafa R.A.
    • Vandvik P.O.
    • Li S.
    • Hao Q.
    • et al.
    Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    BMJ. 2021; 372: 4573https://doi.org/10.1136/bmj.m4573
    View in Article

    • Google Scholar
56. • Wewer Albrechtsen N.J.
    • Albrechtsen R.
    • Bremholm L.
    • Svendsen B.
    • Kuhre R.E.
    • Poulsen S.S.
    • et al.
    Glucagon-like peptide 1 receptor signaling in acinar cells causes growth-dependent release of pancreatic enzymes.
    Cell Rep. 2016; 17: 2845-2856https://doi.org/10.1016/j.celrep.2016.11.051
    View in Article

    • Google Scholar
57. • Hirji I.
    • Andersson S.W.
    • Guo Z.
    • Hammar N.
    • Gomez-Caminero A.
    Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database.
    J Diabetes Complications. 2012; 26: 501-505https://doi.org/10.1016/j.jdiacomp.2012.06.012
    View in Article

    • Google Scholar
58. • Dave C.V.
    • Schneeweiss S.
    • Kim D.
    • Fralick M.
    • Tong A.
    • Patorno E.
    Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study.
    Ann Intern Med. 2019; 171: 248-256https://doi.org/10.7326/M18-3136
    View in Article

    • Google Scholar
59. • Bersoff-Matcha S.J.
    • Chamberlain C.
    • Cao C.
    • Kortepeter C.
    • Chong W.H.
    Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases.
    Ann Intern Med. 2019; 170: 764-769https://doi.org/10.7326/M19-0085
    View in Article

    • Google Scholar
60. • Nathan D.M.
    • Buse J.B.
    • Kahn S.E.
    • Krause-Steinrauf H.
    • Larkin M.E.
    • Staten M.
    • et al.
    Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
    Diabetes Care. 2013; 36: 2254-2261https://doi.org/10.2337/dc13-0356
    View in Article

    • Google Scholar

61. Nathan D.M., Buse J.B., Kahn S.E., Krause-Steinrauf H., Larkin M.E., Staten M., et al. Results of the glycemia reduction approaches in diabetes-a comparative effectiveness (GRADE) Study. American Diabetes Association 81st Scientific Sessions. 2021.

    View in Article

    • Google Scholar
62. • Sharma A.
    • Pagidipati N.J.
    • Califf R.M.
    • McGuire D.K.
    • Green J.B.
    • Demets D.
    • et al.
    Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus: lessons learned and future directions.
    Circulation. 2020; 141: 843-862https://doi.org/10.1161/CIRCULATIONAHA.119.041022
    View in Article

    • Google Scholar